Stockscreener 앱 받기
3.085
2.99%
-0.095
시간 외 거래:
3.09
0.005
+0.16%
전일 마감가:
$3.18
열려 있는:
$3.18
하루 거래량:
253.27K
Relative Volume:
0.32
시가총액:
$347.06M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-1.0458
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
-4.78%
1개월 성능:
-5.95%
6개월 성능:
+97.76%
1년 성능:
+0.49%
1일 변동 폭
$3.08
$3.22
1주일 범위
$3.01
$3.24
52주 변동 폭
$1.05
$3.97
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.085 | 364.50M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics SA Approaches Psychological Resistance Level2025 Valuation Update & AI Powered Trade Plan Recommendations - thegnnews.com
ADC Therapeutics (NYSE:ADCT) Cut to Sell at Wall Street Zen - MarketBeat
Brokerages Set ADC Therapeutics SA (NYSE:ADCT) Target Price at $7.75 - MarketBeat
ADC Therapeutics SA Price Holds Above Key Fib LevelQuarterly Risk Review & Precise Trade Entry Recommendations - newsyoung.net
Equities Analysts Set Expectations for ADCT FY2025 Earnings - MarketBeat
Guggenheim Reiterates Buy Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
RSI + MACD Show Convergence for ADC Therapeutics SAPortfolio Return Report & Free Weekly Chart Analysis and Trade Guides - newsyoung.net
ADC Therapeutics (NYSE:ADCT) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Is ADC Therapeutics SA the Top Chart Pick This WeekMarket Volume Summary & Free Weekly Watchlist of Top Performers - beatles.ru
Is It Too Late to Sell ADC Therapeutics SAWeekly Stock Report & Low Drawdown Momentum Trade Ideas - beatles.ru
Real Time Data Flags Unusual Activity in ADC Therapeutics SAJuly 2025 Fed Impact & High Conviction Buy Zone Picks - metal.it
ADC Therapeutics Reports Q2 2025 Financial Results: Earnings Breakdown and Strategic Maneuvers - AInvest
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - BioSpace
ADC Therapeutics S.A. (NYSE:ADCT) Q2 2025 Earnings Call Transcript - Insider Monkey
ADC Therapeutics 2025 Q2 Earnings Deeper Losses Amid Revenue Growth - AInvest
MACD Cross Could Confirm Trend in ADC Therapeutics SA2025 Biggest Moves & Real-Time Buy Signal Notifications - metal.it
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
ADC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts - MSN
Transcript : ADC Therapeutics SA, Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ADC Therapeutics Reports Second Quarter 2025 Financial Results - TradingView
Can ADC Therapeutics SA weather a recessionConsistent Triple Digit Profits - mustnews.co.kr
Using data models to predict ADC Therapeutics SA stock movementPortfolio Positioning Strategy With Timing - Newser
How to recover losses in ADC Therapeutics SA stockSafe Entry Screening with Data Backed Analysis - Newser
Can volume confirm reversal in ADC Therapeutics SASwing Trade Timing with Daily Forecast - Newser
Will ADC Therapeutics SA stock go up soonWeekly Hot Stocks Based on Volume Flow - Newser
Will ADC Therapeutics SA continue its uptrendFree Value Investing Picks With Stability - Newser
Pattern recognition hints at ADC Therapeutics SA upsideAlpha Trade Flow With Risk Calibration - Newser
Reversal Confirmed ADC Therapeutics SA Stock Rallies Above MALow Risk High Return Opportunities Identified - beatles.ru
Earnings visualization tools for ADC Therapeutics SAFree Weekly Return Pick Forecast Reports - Newser
Is ADC Therapeutics SA reversing from oversold territoryRSI and MACD Signal Summary with Trends - Newser
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 - 富途牛牛
Bank of New York Mellon Corp Decreases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
What’s next for ADC Therapeutics SA stock pricePredictive Analytics for Equity Growth Potential - Newser
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - sharewise.com
What makes ADC Therapeutics SA stock price move sharplySmart Trade Mapping with Entry Details - Newser
Chondrosarcoma Market: Epidemiology, Pipeline Products, Companies Working, Delveinsight Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, As - Menafn
How strong is ADC Therapeutics SA company’s balance sheetCapitalize on emerging growth stocks - Jammu Links News
What is ADC Therapeutics SA company’s growth strategyGet alerts on high-potential stock breakouts - Jammu Links News
How volatile is ADC Therapeutics SA stock compared to the marketMaximize portfolio value with expert tips - Jammu Links News
Does ADC Therapeutics SA stock perform well during market downturnsGet daily updates on top-performing stocks - Jammu Links News
Should I hold or sell ADC Therapeutics SA stock in 2025Achieve rapid growth with smart investments - Jammu Links News
What institutional investors are buying ADC Therapeutics SA stockConsistent triple-digit returns - Jammu Links News
What is the dividend policy of ADC Therapeutics SA stockUnlock exclusive trading strategies for gains - Jammu Links News
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Tuesday - Defense World
Is ADC Therapeutics SA stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.27%
자본화:
|
볼륨(24시간):